Open AccessPCSK9 inhibitors – Clinical viability and practical considerations
Author(s) -
Arulmozhi D. Kandasamy
Publication year - 2017
Publication title -
diabesity
Language(s) - English
Resource type - Journals
ISSN - 2369-0569
DOI - 10.15562/diabesity.2017.39
Subject(s) - alirocumab , medicine , pcsk9 , evolocumab , disease , food and drug administration , pharmacology , drug , cholesterol , apolipoprotein b , lipoprotein , ldl receptor , apolipoprotein a1